Behavioral therapy for treatment of childhood constipation: a randomized controlled trial.
- Conditions
- Functional constipation.
- Registration Number
- NL-OMON23675
- Lead Sponsor
- This research was funded by grants from the MLDS (SWO 02-16).
- Brief Summary
Pediatrics. 2008 May;121(5):e1334-41.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 129
Children aged 4-18 years with functional constipation as defined by the classic Iowa criteria. Patients had to meet at least two of four criteria of pediatric constipation: defecation frequency less than three times per week, fecal incontinence frequency two or more times per week, passage of large amounts of stool at least once every 7-30 days (large enough to clog the toilet), or a palpable abdominal or rectal fecal mass.
Children were excluded from the study if they had already been treated at our gastrointestinal outpatient clinic or had received a comprehensive behavioral treatment in the previous 12 months. In addition, children using drugs influencing gastrointestinal function other than laxative and children with organic causes for defecation disorders such as Hirschsprung's disease, spina bifida occulta, hypothyroidism or other metabolic or renal abnormalities were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Defecation frequency (DF) per week, fecal incontinence frequency (FIF) per week, successful treatment and relapse. Success<br>was defined as DF >= 3 times/week and FIF <= 1 times/two weeks irrespectively of laxative use. A relapse was defined as being unsuccessful at follow-up, while being successful at posttreatment. Assessments were done posttreatment and at 6-months follow-up during a clinical visit or by telephone.
- Secondary Outcome Measures
Name Time Method Secondary outcome measures were: stool-withholding behavior, mean CBCL T-scores and the proportion of children with behavioral scores in the clinical range (T-score>63). Assessments were done posttreatment and at 6-months follow-up during a clinical visit or by telephone.